
Cellectis plans 70% workforce cuts; Sanofi signs $1.2B DNA medicines deal; AstraZeneca buys Omniose
This week in our news roundup: Cellectis’ shift toward in vivo gene editing comes with steep workforce cuts, while Sanofi and AstraZeneca add new technologies through deals. Elsewhere, respiratory developers plan a merger, Lithuania’s Biomatter raises funding and Zealand seeks partners for its rare-disease medicines.
Cellectis plans to cut up to 70% of its workforce: The Paris-based biotech expects the reductions during 2026 and 2027, subject to employee consultation and applicable labor requirements. The cuts follow its September decision to discontinue two clinical-stage allogeneic CAR-T programs and concentrate on treatments that edit genes directly inside patients. Its priorities are HEAL-101, targeting severe hypertriglyceridemia, and HEAL-201, targeting severe hypercholesterolemia. Both remain preclinical, with initial human data expected in 2027 and 2028, respectively. The restructuring targets a cash runway into the second half of 2028.
Sanofi signs $1.2 billion deal with Seawolf on DNA-based medicines: The French drugmaker signed a research collaboration and exclusive license agreement covering bleeding disorders and other undisclosed indications. Seawolf could receive up to $1.2 billion in research, development and commercial milestones, plus royalties; upfront terms were not disclosed. The U.S. biotech’s preclinical platform uses lipid nanoparticles to deliver DNA into cell nuclei, aiming to sustain therapeutic protein production while allowing repeat dosing. Seawolf announced the agreement alongside its emergence from stealth with $100 million raised from investors including Versant Ventures, Novartis Venture Fund and Lilly.
AstraZeneca acquires Omniose for bacterial vaccine technology. The British drugmaker bought its U.S. research partner for an undisclosed sum, making it a wholly owned subsidiary within its infectious disease unit. Omniose’s platform produces and links bacterial sugars and carrier proteins inside a single cell, potentially simplifying the complex manufacturing of conjugate vaccines. These vaccines help the immune system recognize bacterial pathogens. The acquisition follows a collaboration announced in January 2024 and supports AstraZeneca’s preclinical vaccine programs against serious bacterial infections, including threats complicated by antimicrobial resistance.
Nuformix proposes a respiratory drug merger with Biovara: The British company signed largely nonbinding terms for an all-share acquisition envisaged as a merger of equals. It would combine Nuformix’s preclinical inhaled tranilast formulation, NXP002, for fibrotic lung diseases with Biovara’s LipAprep, a reformulation of the anti-nausea drug aprepitant for lung cancer-related cough. LipAprep has completed a single-dose Phase 1 study and is being prepared for further trials. The companies see overlapping potential licensing partners. Completion requires due diligence, definitive agreements and approvals, alongside a planned move from London’s Main Market to AIM.
Biomatter raises $18 million to expand AI enzyme design: The Lithuanian company’s Series A was led by Astanor, with existing investors UVC Partners, Inventure and Metaplanet participating. Funding will support a 2,000-square-meter design-and-testing facility in Vilnius, scheduled to open in 2027, alongside commercial expansion in the U.S. Biomatter designs enzymes for specified chemical reactions and tests them experimentally. It says it has delivered more than 50 custom enzymes to over 25 enterprise customers, including AstraZeneca, BASF and Sanofi. Its work already features in a Thermo Fisher laboratory reagent.
Zealand seeks rare-disease partners as obesity takes priority: The Danish biotech resumed partnering discussions for glepaglutide and is also seeking a partner for dasiglucagon in congenital hyperinsulinism, which causes dangerously low blood sugar, according to Reuters. Glepaglutide subsequently won EU approval on November 13 as Zeydovio for adults with short bowel syndrome. An additional Phase 3 trial is underway to support a U.S. application after the FDA rejected it in 2024. Zealand’s investment increasingly targets obesity, including petrelintide with Roche and survodutide with Boehringer Ingelheim. No timetable for a partnering agreement was disclosed.


